Table 4

Previous ICVD, IHD and VTE in relation to the presence of selected cardiovascular risk factors: logistic regression models

ICVDIHDVTE
UnivariateMultivariableUnivariateMultivariableUnivariateMultivariable
Risk factorOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p ValueOR (95% CI)p Value
Age, years1.05 (1.03 to 1.07)2.4 × 10−61.04 (1.02 to 1.07)0.00071.07 (1.05 to 1.10)7.0 × 10−121.06 (1.04 to 1.09)6.5 × 10−81.02 (1.00 to 1.03)0.031.01 (1.00 to 1.03)
Female1.0 (0.5 to 2.6)1.4 (0.6 to 3.8)0.5 (0.3 to 1.0)0.040.7 (0.3 to 1.5)0.9 (0.5 to 1.8)1.0 (0.5 to 2.1)
Smoking ever1.3 (0.8 to 2.3)2.1 (1.2 to 3.6)0.0061.9 (1.0 to 3.5)0.040.8 (0.5 to 1.2)
Hypertension treatment ±4.8 (2.8 to 8.5)2.7 × 10−83.7 (2.0 to 6.8)1.8 × 10−53.6 (2.2 to 6.2)1.4 × 10−62.3 (1.3 to 4.1)0.0051.6 (1.0 to 2.5)0.051.3 (0.8 to 2.1)
Diabetes1.4 (0.4 to 3.7)5.5 (2.4 to 12.1)3.0 × 10−53.2 (1.3 to 7.8)0.0090.8 (0.3 to 2.4)
SLE duration, years1.06 (1.03 to 1.08)9.3 × 10−71.03 (1.00 to 1.06)0.021.05 (1.03 to 1.07)1.6 × 10−51.02 (0.99 to 1.04)1.00 (0.98 to 1.02)
STAT4 risk alleles*
 1 or 2 vs 0 risk alleles2.9 (1.6 to 5.5)0.00093.3 (1.7 to 6.7)0.00061.05 (0.6 to 1.8)1.2 (0.7 to 2.1)1.3 (0.8 to 2.1)1.3 (0.8 to 2.1)
 1 vs 0 risk alleles2.3 (1.2 to 4.6)0.010.9 (0.5 to 1.6)1.3 (0.8 to 2.0)
 2 vs 0 risk alleles5.3 (2.5 to 11.7)2.5 × 10−51.5 (0.7 to 3.1)1.6 (0.8 to 3.0)
2 vs 1 risk allele2.3 (1.2 to 4.5)0.022.0 (0.9 to 4.0)1.3 (0.6 to 2.4)
aCL IgG2.5 (1.4 to 4.4)0.0022.6 (1.3 to 4.9)0.0050.6 (0.3 to 1.3)2.5 (1.5 to 4.0)0.0003
aCL IgM1.3 (0.7 to 2.3)1.8 (1.0 to 3.1)0.041.8 (0.9 to 3.3)1.4 (0.8 to 2.3)
as2GP-12.0 (1.1 to 3.5)0.020.7 (0.4 to 1.4)2.5 (1.6 to 4.1)0.0002
aPT2.0 (1.0 to 3.8)0.040.8 (0.3 to 1.7)1.5 (0.8 to 2.6)
≥2aPL2.4 (1.3 to 4.1)0.0031.0 (0.5 to 1.9)2.6 (1.6 to 4.1)0.00012.5 (1.5 to 4.1)0.0002
Mid Sweden vs southern Sweden0.9 (0.5 to 1.6)1.0 (0.7 to 1.3)1.3 (0.8 to 2.3)1.0 (0.7 to 1.3)0.8 (0.6 to 1.0)0.050.8 (0.6 to 1.0)
  • p Values. 0.05 are presented.

  • * Number of STAT4 rs10181656(G), risk alleles (0,1 or 2).

  • ≥2aPL: two or more positive tests among aCL IgG, aCL IgM, aβ2GP-1 or aPT; a, anti; β2GP-1, β2 glycoprotein 1; CL, cardiolipin, ICVD, ischaemic cerebrovascular disease; IHD, ischaemic heart disease; PL, phospholipids; PT, prothrombin; SLE< systemic lupus erythematosus; VTE, venous thromboembolism.